&w=3840&q=100)
Just 8% of bacterial infections in India treated aptly in 2019: Report
Findings published in The Lancet Infectious Diseases journal show that in 2019, there were nearly 15 lakh bacterial infections resistant to carbapenems -- a common antibiotic -- across eight countries that were under study.
Carbapenems are used for treating severe infections -- such as those acquired from being inside a hospital, where bacteria resistant to antibiotics are abundant.
Of the 15 lakh bacterial infections, only over a lakh treatment courses were procured -- the resulting treatment gap meant that only 6.9 per cent of the patients were treated appropriately, researchers, including those from the Global Antibiotic Research and Development Partnership (GARDP), Switzerland, found.
"India procured most of the treatment courses (80.5 per cent; 83,468 courses), with 7.8 per cent of infections treated appropriately," the authors wrote.
The eight countries that were part of the study included Bangladesh, Pakistan and Mexico.
The most-procured antibiotic was tigecycline -- usually prescribed in hospitals for serious infections.
Most of the 15 lakh infections were found to have occurred in South Asia, with over 10 lakh infections estimated to have occurred in India.
Antibiotic, or antimicrobial, resistance is emerging as a major public health, with a 2024 Lancet study projecting over 39 million around the world could die due to such infections in the coming 25 years -- most of these could occur in South Asia, it said.
The study also estimated that over a million died every year during 1990-2021 from antibiotic resistance, in which disease-causing bacteria become immune to drugs developed to kill them, thereby rendering these drugs ineffective.
For this study, data from a systematic analysis of the burden of bacterial antimicrobial resistance from 1990 to 2021 -- named 'GRAM' study -- was analysed, along with that from a health-care database managed by IQVIA, a US-based life sciences company.
The authors said the findings highlight the most recently available picture of the state of care for antimicrobial-resistant infections in the selected low- and middle-income countries.
The results also underscore the need for meaningful action by global and national policy makers, the team said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
20 minutes ago
- Indian Express
PixxelSpace-led consortium to make country's first commercial earth observation constellation
A private consortium of four space start-ups led by Bengaluru-based PixxelSpace has won a bid to build and run the country's fully-indigenous commercial earth observation satellite constellation, the Indian National Space Promotion and Authorisation Centre (IN-SPACe) said Tuesday. According to the agreement, the consortium will invest Rs 1,200 crore over next five years to set up the 12-satellite constellation. It will own, manufacture, launch, develop ground infrastructure, operate the satellite constellation as well as commercialise the data generated. 'By generating high-resolution, indigenous satellite data, the initiative will significantly reduce India's reliance on foreign sources, ensure data sovereignty, and position the country among the global leaders,' said IN-SPACe. The bid for partnership with the government — which will provide technical and policy support — was won by the consortium of PixxelSpace, Piersight Space, Satsure Analytics India, and Dhruva Space, at the financial stage. At least two other consortiums, led by Astra Microwave Products and GalaxEye Space, had also been shortlisted after a technical evaluation. The satellites will be equipped with panchromatic, multispectral, hyperspectral, and microwave SAR sensors — which can produce images of the Earth in varying degrees of detail. The data would be used in the fields of agriculture, infrastructure development and urban planning, disaster management, security, as well as climate change monitoring. '(This) demonstrates the capability and confidence of Indian companies to lead large-scale, technologically advanced, and commercially viable space missions that serve both national and global markets,' said Dr Pawan Goenka, IN-SPACe Chairman. The constellation will be deployed in a phased manner over four years to ensure continuous service upgrades and expanded coverage. Once the constellation becomes operational, it will be among the most advanced earth observation systems in the world. 'We are grateful to IN-SPACe and the Government of India for trusting our consortium with this historic mission. Together with our partners Satsure, Dhruva and PierSight, we look forward to building world-class space-tech capabilities that serve the whole planet from Indian soil. This is India's moment to lead the world in space-powered solutions,' said Awais Ahmed, CEO of PixxelSpace.
Mint
an hour ago
- Mint
India approves its first Maxar-like private satellite data project worth $135mn
A consortium of four startups, led by Bengaluru-based Pixxel, has won a mandate to create and operate India's first privately-built satellite imaging system. Approved by the country's space regulator on Tuesday, the project worth $135 million ( ₹ 1,200 crore) over five years, will see the birth of private Indian space firms that sell earth observation data at scale to commercial clients. The move mimics an established American model of satellite operation, where firms such as Maxar Technologies sell high-resolution satellite images to any paying customer, for a fee. While Maxar's data ran into a controversy when reports highlighted its involvement in the planning of the Pahalgam terror attack in Jammu & Kashmir on 22 April, industry stakeholders have consistently flagged the importance of the technology in modern-day industries—such as civic planning, forestry, agriculture, disaster management, maritime exploration and more. In the mission, Pixxel, along with fellow startups Dhruva, SatSure and Piersight, will develop a constellation of 12 satellites with 'panchromatic, multispectral, hyperspectral, and microwave SAR sensors'—a statement by the Indian National Space Promotion and Authorization Centre (In-Space) said. While the description does not specify a resolution of data, it refers to images that can clearly convey close-range information such as depth and textures. Pawan Goenka, chairman of In-Space, said in the statement that the project 'demonstrates the capability and confidence of Indian companies to lead large-scale, technologically advanced, and commercially viable space missions that serve both national and global markets.' However, he could not be reached for a comment on the government's role in the project. The constellation project, once completed, will become the first private imaging system in India. In-Space did not reveal the breakdown of the final bids till press time. In June, In-Space kicked up a row for awarding a $60-million contract to privatize the Indian Space Research Organisation (Isro)'s small satellite launch vehicle to state-run Hindustan Aeronautics Ltd (HAL). The Centre holds over 70% stake in HAL, leaving analysts wondering whether the sale of the government-built rocket truly qualified as privatization. Industry stakeholders had also raised concerns around stifling of the private sector, at a time when HAL struggled to deliver on previous Isro and Air Force contracts. Tuesday's announcements appear to have made amends by awarding a large commercial contract to private space firms. While the government has thrown open the space sector to private players, various industry veterans, including former Isro chief S. Somanath, have raised concerns over the Centre not being the anchor customer for India's nascent space industry. They fear that without the government's regular and guaranteed orders, the startups may not be able to grow. 'There is no clear statement of intent that for the new private satellite constellation, the government will be an anchor customer. But, this is a sign of intent that India is ready to offer contracts exceeding a few hundred thousand dollars to private companies—which in turn would help the industry grow further,' a senior industry executive said, requesting anonymity, since he was a part of the bidding process for this very contract. Earth observation satellites, Mint reported on 13 July, is giving an increasing fillip to India's space startups in terms of revenue and client base—as governments as well as private firms see a more geopolitically divided world. However, while the likes of Digantara applied and won a ministry of defence surveillance satellite contract, Pixxel itself is a part of an increasing number of companies setting up shop in the US for more lucrative American space contracts. Other finalists of the imaging satellite project included public-sector firm Bharat Electronics, and Bengaluru-based startup GalaxEye—which is also building its own surveillance satellite to offer as a product or service around the world.
Mint
an hour ago
- Mint
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
(Bloomberg) -- If Novo Nordisk A/S's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.' It's not uncommon for drugmakers to study combinations of treatments when two seem to work for the same condition, in hope of boosting the benefit. Viehbacher said if Novo's study works, Biogen 'might' do trials looking at the two drugs in combination but cautioned the timeline might not make sense given Alzheimer's studies take years to complete. Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30% of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39% tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. More stories like this are available on
